

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Mutations in which of the following breast cancer susceptibility genes were most prevalent among women with breast cancer assessed in the CARRIERS population-based study?**
 - BRCA1
 - BRCA2**
 - ATM
 - PALB2
- Which of the following any-grade adverse events was the most common in patients receiving olaparib for HER2-negative localized breast cancer in the OlympiA trial?**
 - Neutropenia
 - Diarrhea
 - Fatigue
 - Nausea**
 - Anemia
- Which of the following combination trials demonstrated a benefit to combining carboplatin and paclitaxel with veliparib for patients with advanced breast cancer with HER2 and germline BRCA1/2 mutations?**
 - MEDIOLA
 - GEPAROLA
 - BROCADE**
 - TOPACIO
- In the Phase III EMBRACA trial evaluating talazoparib versus standard therapy for patients with metastatic breast cancer and germline BRCA1/2 mutations, which of the following progression-free survival (PFS) results was reported with talazoparib?**
 - Median PFS was significantly longer**
 - Median PFS was similar to that with standard therapy
 - Median PFS was significantly longer
- Overall survival subgroup analysis from the OlympiA trial evaluating adjuvant olaparib for patients with HER2-negative breast cancer and germline BRCA mutations revealed that which of the following groups derived the most benefit as measured by hazard ratio?**
 - Patients who had previously received adjuvant chemotherapy
 - Patients with hormone receptor-positive disease
 - Patients with BRCA1 mutations
 - Patients with BRCA2 mutations**